Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF | R&D Systems 7147-IR-100 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF

catalog :

7147-IR-100

quantity :

100 ug

price :

480 USD

citations: 7

Reference
Bagley S, Logun M, Fraietta J, Wang X, Desai A, Bagley L, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30:1320-1329 pubmed publisher
Pawlowski K, Duffy J, Tiwari A, Zannikou M, Balyasnikova I. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas. Cells. 2023;12: pubmed publisher
Stern L, Gholamin S, Moraga I, Yang X, Saravanakumar S, Cohen J, et al. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy. Proc Natl Acad Sci U S A. 2022;119:e2112006119 pubmed publisher
Brown C, Aguilar B, Starr R, Yang X, Chang W, Weng L, et al. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther. 2018;26:31-44 pubmed publisher
Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, et al. Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma. Neuro Oncol. 2017;: pubmed publisher
Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, et al. Cytokine induction of VCAM-1 but not IL13R?2 on glioma cells: a tale of two antibodies. PLoS ONE. 2014;9:e95123 pubmed publisher
Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21:2087-101 pubmed publisher

product information

master code :

7147-IR

SKU :

7147-IR-100

product name :

Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF

unit size :

100 ug

description :

The Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF from R&D Systems is derived from CHO. The Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF has been validated for the following applications: Bioactivity.

target :

IL-13 R alpha 2

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

observed molecular weight :

75-95 kDa, reducing conditions

theoretical molecular weight :

64 kDa (monomer)

gene symbol :

IL13RA2

details of functionality :

Measured by its ability to inhibit IL-13-dependent proliferation of TF-1 human erythroleukemic cells. Kitamura, T. et al . (1989) J. Cell Physiol. 140 :323. The ED50 for this effect is 0.1-0.5 ╡g/mL in the presence of 8 ng/mL recombinant human IL-13.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

NP_000631.1

applications :

Bioactivity

source long :

Chinese Hamster Ovary cell line, CHO-derived human IL-13 R alpha 2 protein Human IL-13 R alpha 2 (Cys22-Leu342) Accession # NP_000631 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus

source short :

CHO

USD :

480 USD

alt names :

cancer/testis antigen 19, CD213a2, CD213a2 antigen, CT19, IL-13 receptor subunit alpha-2, IL13BP, IL13R, IL-13R, IL13R alpha 2, IL-13R subunit alpha-2, IL13RA2, IL-13RA2, IL-13R-alpha-2, interleukin 13 binding protein, interleukin 13 receptor alpha 2 chain, interleukin 13 receptor, alpha 2, interleukin-13 receptor subunit alpha-2, Interleukin-13-binding protein

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.